Retrospective analysis observes 8.5% incidence of intraocular inflammation in patients receiving bilateral faricimab injections, highlighting potential risks.
Purpose: To evaluate the incidence of intraocular inflammation (IOI) after intravitreal (IVT) faricimab injection. Methods: A retrospective observational study was performed of all patients who received IVT faricimab injections at NHS Highland between January 2023 and June 2024 and subsequently developed IOI. Results: IOI was seen in 11 eyes of 6 patients after faricimab injection. All aqueous and vitreous cultures were negative. Among patients who received bilateral faricimab injections, the incidence of IOI was 8.5% (5/59). Four eyes experienced a vision loss of 11.5 ± 8.6 Early Treatment Diabetic Retinopathy Study letters. Cases were characterized by a delayed onset of subacute symptoms after injection, keratic precipitates, and elevated intraocular pressure. Conclusions: Although the overall incidence of faricimab-related IOI is low, our findings highlight the need for increased vigilance in patients receiving bilateral faricimab injections.
No takes yet. Share an insight, caveat, or question.
Dhillon et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: